Drug
MK 8690
MK 8690: highest development phase Phase 2, developed by Merck. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| MK-8690 NCT07463183 | Phase 2 | Colitis Ulcerative |
Latest
No recent events.
Follow MK 8690 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.